Takeda’s Ninlaro fails phase 3 amyloidosis trialTakeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share XTakeda’s Ninlaro fails phase 3 amyloidosis trialhttps://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
